A Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Latest Information Update: 28 Jul 2025
At a glance
- Drugs SOF SKN (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms HERACLES
- Sponsors Noxopharm
Most Recent Events
- 20 Jul 2025 Status changed from not yet recruiting to recruiting.
- 18 Jul 2025 Status changed from planning to not yet recruiting.
- 02 May 2025 According to a Noxopharm media release, company has applied for Human Research Ethics Committee (HREC) approval for the HERACLES clinical trial.